[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352823-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352823-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","assessing-antitumor-effects-of-plasma-activated-phosphate-buffered-saline-in-breast-cancer-cell-2d-and-3d-models","Assessing antitumor effects of plasma-activated phosphate buffered saline in breast cancer cell 2D and 3D models","","Cold plasma-based therapy is explored through plasma-activated phosphate-buffered saline (PAPBS), evaluated against human breast adenocarcinoma cells and paclitaxel-resistant counterparts. A streamer corona discharge cold atmospheric plasma activates PBS, and a 1-hour PAPBS incubation reduces viability and triggers apoptosis in both MCF-7 and MCF-7/PAX. In 3D spheroid tumor models, PAPBS suppresses growth and induces shrinkage depending on treatment time and exposure duration. RONS-enriched PAPBS also overcomes acquired drug resistance, supporting a promising anticancer therapeutic strategy for resistant breast tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/assessing-antitumor-effects-of-plasma-activated-phosphate-buffered-saline-in-breast-cancer-cell-2d-and-3d-models/352823/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/assessing-antitumor-effects-of-plasma-activated-phosphate-buffered-saline-in-breast-cancer-cell-2d-and-3d-models/352823.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is PAPBS and how is it prepared?","Question",{"text":63,"@type":64},"PAPBS refers to plasma-activated phosphate-buffered saline. It is prepared by activating PBS using a cold atmospheric plasma with streamer corona discharge.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PAPBS affect paclitaxel-sensitive and -resistant breast cancer cells?",{"text":68,"@type":64},"After a 1-hour incubation, PAPBS significantly reduces cell viability and triggers apoptosis in both MCF-7 cells and the paclitaxel-resistant MCF-7/PAX subline.",{"name":70,"@type":61,"acceptedAnswer":71},"How does PAPBS perform in 3D breast cancer tumor models?",{"text":72,"@type":64},"PAPBS inhibits growth of 3D spheroids and causes shrinkage depending on plasma treatment time and exposure duration, with resistant 3D models losing viability after 24-hour treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352823,1791032999,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAssessing antitumor effects of plasma-activated phosphate buffered saline in breast cancer cell 2D and 3D models  \nDarina Kužmová1, Helena Gbelcová2 & Zdenko Machala1􀀍  \nCold plasma-based therapy shows potential as a new method of tumor reduction, especially beneficial for patients who do not respond positively to conventional therapy or struggle with health complications associated with such treatment. This study investigates the plasma-activated phosphate-buffered saline (PAPBS) that exhibits significant antitumor efficacy against human breast adenocarcinoma cells in a dose-dependent manner. The activation of phosphate-buffered saline (PBS) was performed using a cold atmospheric plasma of streamer corona discharge. By testing PAPBS on both paclitaxel-sensitive MCF-7 human breast adenocarcinoma cell line and its paclitaxel-resistant subline, MCF-7/PAX, it is shown that PAPBS significantly reduced cell viability and triggered apoptosis in both cell lines after a 1-h incubation. PAPBS effectively inhibited the growth of breast cancer cell 3D physiologically relevant tumor models—spheroids and caused their shrinkage depending on plasma treatment time and the duration of PAPBS exposure. Furthermore, cells in 3D models of resistant breast tumor cells completely lost their viability after 24-h treatment with PAPBS treated 30 min by plasma. These findings indicate that PAPBS enriched by RONS can overcome acquired drug resistance in breast cancer, representing a promising anticancer therapeutic strategy.  \nKeywords Cold plasma, Plasma-activated liquid, Antitumor effect, Breast cancer, Chemotherapy resistance, Spheroids  \nDespite decades of intensive research and development of anticancer therapies, cancer remains the second leading cause of death worldwide. For women, breast cancer is the most frequently diagnosed malignancy and one of the leading causes of cancer-related mortality, surpassing both lung and colorectal cancers. This reality highlights the urgent need for innovative therapeutic strategies against breast cancer. Approaches that can enhance existing treatments aim for curative outcomes while minimizing adverse effects, and in palliative care, improve patients’ quality of life 1. Although chemotherapy is a key strategy for breast cancer treatment, whether it is used as a neoadjuvant, adjuvant, or primary therapy, it faces challenges when breast cancer tumors exhibit drug resistance. This lack of a tumor response can be intrinsic or acquired, where initially sensitive tumors develop resistance during treatment 2.  \nPlasma medicine represents a potential innovative strategy in the fight against cancer. Cold atmospheric plasma (CAP) generates a reactive environment with extensive potential across a broad range of biomedical applications, from the sterilization of medical instruments to direct interactions with cells and tissues, the treatment of various skin diseases and the enhancement of wound healing 3. However, there is a growing emphasis on studies demonstrating its antitumor effect and potential in cancer treatment.  \nThe antitumor effect of CAP is mainly attributed to the reactive oxygen and nitrogen species (RONS) generated in the plasma due to the physical–chemical processes of the interaction of the plasma and ambient air. These species include hydroxyl radicals ·OH, hydrogen peroxide H2O2, nitrogen oxides N2O, NO, NO2, ozone O3, and superoxide O2· −4 .  \nRONS are involved in numerous physiological processes, including cell signaling, the immune response, and homeostasis 5. They also function as important signaling molecules that regulate various aspects of cancer, including cell proliferation, survival, angiogenesis, and metastasis.  \n1Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Mlynská Dolina, Bratislava, Slovakia. 2Faculty of Medicine, Comenius University, Špitálska 24, 813 72 Bratislava, Slovakia. 􀀍 ","cbCaiqgdgpckwbnv","https://ap.wps.com/l/cbCaiqgdgpckwbnv","pdf",10968568,18,"English","# Introduction\n## Rationale for innovative breast cancer therapies\n## Challenges of chemotherapy and drug resistance\n# Plasma medicine and mechanism\n## Cold atmospheric plasma and RONS generation\n## RONS in physiology and cancer regulation\n## Dose-dependent effects and apoptosis activation\n# Selectivity against cancer cells\n## Therapeutic dose window versus normal cells\n## Proposed mechanisms: aquaporins and membrane susceptibility","[{\"question\":\"What is PAPBS and how is it prepared?\",\"answer\":\"PAPBS refers to plasma-activated phosphate-buffered saline. It is prepared by activating PBS using a cold atmospheric plasma with streamer corona discharge.\"},{\"question\":\"How does PAPBS affect paclitaxel-sensitive and -resistant breast cancer cells?\",\"answer\":\"After a 1-hour incubation, PAPBS significantly reduces cell viability and triggers apoptosis in both MCF-7 cells and the paclitaxel-resistant MCF-7/PAX subline.\"},{\"question\":\"How does PAPBS perform in 3D breast cancer tumor models?\",\"answer\":\"PAPBS inhibits growth of 3D spheroids and causes shrinkage depending on plasma treatment time and exposure duration, with resistant 3D models losing viability after 24-hour treatment.\"}]","Assessing antitumor effects of plasma-activated phosphate buffered saline in breast cancer cell 2D and 3D models | PDF",1790101534,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6aa7ea0d67560a2277b1dd3bf8b987e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56dfdff15762551d63b4f2e40edee97e.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d758ca18dda86962893cb642c2e024e.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1167af555f1df671088465007305849.webp",980,1287]